VRTX — VERTEX PHARMACEUTICALS INC / MA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 875320 ·
Last close
$534.20
Market Cap
$135.44B
52W High
$568.67
52W Low
$412.27
ADV30
1,512,144
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 3,440,800,000 | 2,914,700,000 | 750,000,000 | 653,600,000 | 32,736,300,000 | 4,979,300,000 | 11,828,900,000 |
| Jun 2026 | 3,333,900,000 | 2,844,700,000 | 1,268,700,000 | 1,099,800,000 | 27,423,300,000 | 6,143,500,000 | 7,175,400,000 |
| Mar 2026 | 2,986,900,000 | 2,594,100,000 | 1,138,800,000 | 1,031,400,000 | 26,484,400,000 | 5,492,900,000 | 7,122,500,000 |
| Dec 2025 | 3,190,000,000 | 2,724,000,000 | 1,130,300,000 | 1,191,100,000 | 25,643,000,000 | 5,084,800,000 | 6,977,200,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$3,694,600,000
Investing CF
$-6,866,400,000
Financing CF
$3,254,200,000
CapEx
$-492,300,000
Dividends Paid
—
Buybacks
$-1,376,100,000
EPS Diluted TTM
$15.54
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$16,344,800,000
Inventory
$2,245,300,000
Receivables
$2,311,000,000
ST Investments
$1,324,000,000
EBIT TTM
$4,561,200,000
Pretax Income TTM
$4,759,100,000
Interest Exp TTM
$46,300,000
Analysts
28
Yahoo Snapshot (yfinance, live)
Total Revenue
$12,951,600,128
EBITDA
$5,100,800,000
Free Cash Flow
$2,337,787,392
Enterprise Value
$138,883,022,848
Total Cash
$6,303,300,096
Total Debt
$6,478,400,000
Shares Out
253,537,674
Trailing EPS
$15.54
Book Value
$82.47
ROE
20.8%
ROA
10.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,001,300,000 | 4,554,400,000 | 3,953,200,000 | 25,643,000,000 | 6,977,200,000 | 18,665,800,000 | 3,631,400,000 |
| Dec 2024 | 11,020,100,000 | -233,400,000 | -535,600,000 | 22,533,200,000 | 6,123,600,000 | 16,409,600,000 | -492,600,000 |
| Dec 2023 | 9,869,200,000 | 3,780,400,000 | 3,619,600,000 | 22,730,200,000 | 5,149,800,000 | 17,580,400,000 | 3,537,300,000 |
| Dec 2022 | 8,930,700,000 | 4,249,900,000 | 3,322,000,000 | 18,150,900,000 | 4,238,200,000 | 13,912,700,000 | 4,129,900,000 |
TTM Snapshot
Revenues TTM
$12,587,200,000
NetIncome TTM
$4,405,200,000
OpCashFlow TTM
—
Assets (Latest)
$27,423,300,000
Forward EPS
$19.92
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $410.00 · spot: $536.45 · call volume: 240 · put volume: 696
Expected Move to 2027-01-15:
±$60.90
(11.35%) —
implied range
$475.55 –
$597.35
· ATM straddle on $540.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVO | NOVO NORDISK A S | $136.10B | $40.70 | — |
| BMY | BRISTOL MYERS SQUIBB CO | $125.40B | $61.35 | — |
| SNY | Sanofi | $113.89B | $47.53 | — |
| PFE | PFIZER INC | $162.27B | $28.47 | — |
| ABT | ABBOTT LABORATORIES | $181.35B | $104.71 | — |
News headlines (Yahoo Finance, 1h cache)
Genomics, Vertex extend drug discovery alliance in $220m deal
2026-11-19 10:53 · Yahoo
Should You Pick Vertex Stock Over Its Biotech Rivals?
2026-11-18 17:13 · Yahoo
Genomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex Pharmaceuticals
2026-11-18 09:43 · Yahoo
Vertex Pharmaceuticals (VRTX) Stock May Be Undervalued After Its 187% Run
2026-11-18 05:13 · Yahoo
Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus
2026-11-18 03:12 · Yahoo
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
2026-11-17 23:47 · Yahoo
Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom
2026-11-17 20:12 · Yahoo
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
2026-11-17 15:00 · Yahoo
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
2026-11-16 12:12 · Yahoo
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
2026-11-13 23:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.